

## AMENDMENT TO THE CLAIMS

Claims 1-17: Canceled.

18. (Currently amended) A method for treating a developmental defect or a disease of the eye in a human, said method comprising ~~increasing the FREAC3 biological activity in a mammal diagnosed as having developmental defect or a disease of the eye~~ administering a composition comprising a biologically active FREAC3 polypeptide having 95% sequence identity to SEQ ID NO:2 and a pharmaceutically acceptable carrier.

19. (Previously presented) The method of claim 18, wherein said disease of the eye is glaucoma.

20. (Previously presented) The method of claim 18, wherein said developmental defect of the eye is characterized by anterior segment dysgenesis.

21. (Previously presented) The method of claim 18, wherein said developmental defect of the eye is Axenfeld-Reiger Anomaly.

Claim 22: Canceled.

23. (Withdrawn) The method of claim 22, wherein said number of biologically active FREAC3 molecules is increased by *in vivo* gene therapy.

24. (Withdrawn) The method of claim 23, wherein said *in vivo* gene therapy comprises inserting into the cells of the eye of said mammal a wild-type FREAC3 nucleic acid.

25. (Withdrawn) The method of claim 24, wherein said wild-type FREAC3 nucleic acid is operable linked to a promoter.

26. (Withdrawn) The method of 23, wherein said wild-type FREAC3 nucleic acid is inserted in said cells of the eye using a viral vector.

Claim 27: Canceled.

28. (Currently amended) The method of ~~claim 27~~ claim 18, wherein said pharmaceutically acceptable carrier is physiological saline.

29. (Currently amended) The method of ~~claim 27~~ claim 18, wherein said composition is delivered by ophthalmic administration.

30. (Currently amended) The method of ~~claim 27~~ claim 18, wherein said composition is delivered by intraorbital administration.

31. (Currently amended) The method of ~~claim 27~~ claim 18, wherein said ~~wild-type~~ FREAC3 polypeptide is substantially pure.

Claim 32: Canceled.

33. (New) The method of claim 18, wherein said biologically active FREAC3 polypeptide is selected from the group consisting of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, a polypeptide comprising the amino acid sequence of SEQ ID NO:2 and having glycine inserted at position 375, and a polypeptide comprising the amino acid sequence of SEQ ID NO:2 and having a glycine inserted at position 447.